The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 601–700 of 838
Shimada, Y., Nakano, M., Matsumoto, A., Ozeki, H., Abe, K., Tajima, Y., Yamai, D., Nogami, H., Nakano, M., Tani, T., et al. (2025) · Cancers · doi:10.3390/cancers17132233 · Cited by 4
Adjuvant Therapy for Cutaneous Melanoma
Schuitevoerder, D., Vining, C. C., & Tseng, J. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.02.009 · Cited by 4
Checkpoint-Inhibitoren – Indikation und Verwendung bei Melanompatienten
Lamos, C., & Hunger, R. E. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00870-8 · Cited by 4
Barsoumian, H. B., Sheth, R. A., Ramapriyan, R., Hsu, E. Y., Gagea, M., Crowley, K., Sezen, D., Williams, M. L., & Welsh, J. W. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.101137 · Cited by 5
Li, K., Chen, S., Wang, C., Li, X., & Li, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132466 · Cited by 4
Karna, R., Deliwala, S. S., Ramgopal, B., Asawa, P., Mishra, R., Mohan, B. P., Jayakrishnan, T., Grover, D., Kalra, T., Bhalla, J. S., et al. (2023) · Immunotherapy · doi:10.2217/imt-2023-0001 · Cited by 4
Konishi, K., Okamoto, M., Tokumitsu, R., Yano, M., Nasu, K., & Kobayashi, E. (2024) · Medical Molecular Morphology · doi:10.1007/s00795-023-00377-6 · Cited by 4
Suzuki, S., Tsuzuki, T., Saito, M., Ishii, T., Takahara, T., Satou, A., Inukai, D., Yamanaka, S., Yoshikawa, K., Ueda, R., et al. (2024) · Pathology international (Print) · doi:10.1111/pin.13430 · Cited by 4
Truong, T., Kennedy, L. B., & Patel, S. P. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01232-0 · Cited by 4
Self-citationImmunotherapies in non-metastatic gastrointestinal cancers
Saúde-Conde, R., Nguyen, D. J. M., & Hendlisz, A. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000956 · Cited by 4
Murakami, H., Takahama, S., Akita, H., Kobayashi, S., Masuta, Y., Nagatsuka, Y., Higashiguchi, M., Tomokuni, A., Yoshida, K., Takahashi, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363568 · Cited by 4
Digital spatial profiling for pathologists
Donati, B., Manzotti, G., Torricelli, F., Ascione, C., Valli, R., Santandrea, G., Ragazzi, M., Zanetti, E., Ciarrocchi, A., & Piana, S. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03955-w · Cited by 3
Yoo, S. A., & Lee, J. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110729 · Cited by 3
Self-citationPang, Y., Zhao, X., Guo, X., Han, J., & Ji, Y. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf368 · Cited by 6
Sun, X., Ocampo, A. A., Hanna, A., Taylor, B. C., Marshall, J. L., Steele, J. A., Axelrod, M. L., Wescott, E. C., Opalenik, S. R., DeMichele, A. M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aec2358 · Cited by 3
Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis
Lv, K., Du, X., Chen, C., & Yu, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1361530 · Cited by 3
Hegyi, B., Csikó, K. G., Balatoni, T., Fröhlich, G., Bőcs, K., Tóth, E., Mohos, A., Neumark, A. R., Menyhárt, C. D., Ferrone, S., et al. (2024) · Biomolecules · doi:10.3390/biom14121609 · Cited by 2
van Akkooi, A. C. J., Ariyan, C. E., & Moncrieff, M. D. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18163-2 · Cited by 4
Albers, E. A. C., Luijendijk, M. J., Egeler, M., Fraterman, I., Lucas, M. W., de Ligt, K. M., Schagen, S. B., Blank, C., & Poll-Franse, L. V. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115710 · Cited by 3
La neoadyuvancia: una nueva oportunidad para cambiar la cirugía del melanoma
Boada, A. (2021) · Piel · doi:10.1016/j.piel.2021.02.001 · Cited by 3
Yano, M., Nasu, K., Yasuda, M., Katoh, T., Kagabu, M., Kobara, H., Matsuura, M., Tokuyama, O., Yamawaki, T., Wakahashi, S., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000811 · Cited by 3
Recent advances in transcriptomic biomarker detection for cancer
Thakur, S., & Ghosh, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91810-7.00007-8 · Cited by 3
Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment
Chen, H., Pu, S., Mei, N., Liu, X., He, J., & Zhang, H. (2022) · Cancer Biomarkers · doi:10.3233/cbm-220073 · Cited by 3
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 3
Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
Dubus, M., Charles, J., Leccia, M. ‐., Mouret, S., & Trabelsi, S. (2023) · JAAD Case Reports · doi:10.1016/j.jdcr.2023.05.037 · Cited by 3
Ologun, G. O., Jones, C. P., Landrum, K. R., Pham, V. P., Ismail, S., Long, P. K., Sorah, J. D., Stitzenberg, K. B., Meyers, M. O., & Ollila, D. W. (2024) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000969 · Cited by 3
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner
Tilsed, C. M., Morales, M. L. O., Zemek, R. M., Gordon, B. A., Piggott, M., Nowak, A. K., Fisher, S. A., Lake, R., & Lesterhuis, W. J. (2024) · BMC Cancer · doi:10.1186/s12885-024-11915-5 · Cited by 3
Feng, Y., Guo, K., Jin, H., Jiang, J., Wang, M., & Lin, S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2325404 · Cited by 3
Emerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies
Lins, D. S. D. R., Awni, B. M., Pereira, A. Z. L., de Menezes, J. N., Bertolli, E., Belfort, F. A., & Munhoz, R. R. (2024) · Medical Sciences · doi:10.3390/medsci12030035 · Cited by 5
Advances in Adjuvant and Neoadjuvant Therapy for Melanoma
Sierra-Davidson, K., & Boland, G. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.007 · Cited by 3
Anticancer mechanisms and applications based on γδ T cells in cancer immunotherapy
Yang, Q., Na, J., Qin, S., Su, J., Huang, H., & Zhong, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104814 · Cited by 3
The path forward for anti-programmed cell death-1 therapy in gliomas
Majd, N., Kamiya-Matsuoka, C., & de Groot, J. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000746 · Cited by 3
Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
Sarver, M. M., Brown, M. C., Rhodin, K. E., Salama, A. K. S., & Beasley, G. M. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1943987 · Cited by 3
Davari, D. R., Orlow, I., Kanetsky, P. A., Luo, L., Edmiston, S. N., Conway, K., Parrish, E., Hao, H., BUSAM, K. J., Sharma, A., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0686 · Cited by 3
Neoadjuvant Nivo/Rela for Resectable Melanoma
Miller, D. M., Kaufman, H. L., Emerick, K. S., Ear, M. E. A., Cohen, J. V., Kim, E., & Shalhout, S. Z. (2022) · Journal of Cutaneous Oncology · doi:10.59449/joco.2022.12.05 · Cited by 3
New window of opportunity with ICIs in melanoma
Killock, D. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0124-x · Cited by 3
Tarhini, A. A., Hanayneh, W., Powers, J. J., Segura, C. M. M., Conejo-Garcia, J. R., Lam, C. A., Hakam, A., & Hoffman, M. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1044587 · Cited by 3
Amiryousefi, A., Wala, J. A., Lin, J., Labadie, B. W., Atmakuri, A., Maliga, Z., Toye, E., Chaudagar, K. K., Torcasso, M. S., Coy, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.21.677465 · Cited by 3
Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma
Nair, U., Rakestraw, E., Beasley, G. M., & O'Connor, M. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062427 · Cited by 2
Wang, Y., Tang, C., Wang, K., Zhang, X., Zhang, L., Xiao, X., Lin, H., & Xiong, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177561 · Cited by 3
Ophuis, C. M. C. O., & van Akkooi, A. C. J. (2025) · Surgical Oncology Insight · doi:10.1016/j.soi.2025.100186 · Cited by 2
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
Immune-microbiome coordination defines interferon setpoints in healthy humans
Babdor, J., Patel, R. K., Davidson, B. R., Koser, K. L., Noecker, C. A., Rahim, M. K., Bisanz, J. E., Tenvooren, I., Marquez, D., Calvo, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.003 · Cited by 4
Han, J., Zhou, J., Dwivedy, A., Xue, T., Bhatta, R., Liu, Y., Nguyen, D., Yang, B., Wang, Y., Wang, X., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504976123 · Cited by 4
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Ascierto, P. A., Bruzzi, P., Eggermont, A. M. M., Hamid, O., Tawbi, H. A., van Akkooi, A. C. J., Testori, A., Caracò, C., Puzanov, I. J., & Perrone, F. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1892-5 · Cited by 2
Self-citationSkin melanoma. State of the problem. Review
Yargunin, S. A., & Lazarev, A. F. (2020) · Russian Journal of Oncology · doi:10.18821/1028-9984-2019-24-3-6-113-120 · Cited by 4
Park, J. H., Park, Y. M., Kim, D., Kim, S., Kim, H. R., & Koh, Y. W. (2022) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2022.00283 · Cited by 2
Modern aspects of immunotherapy with checkpoint inhibitors in melanoma
Vladimirova, L. Y., Teplyakova, M. A., Попова, И. Л., Абрамова, Н. А., Tikhanovskaya, N. M., Льянова, А. А., Эдуардовна, С. А., Алексеевна, Р. Л., Kabanov, S. N., Kalabanova, E. A., et al. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-26-35-40 · Cited by 2
Immunotherapy in cancer: Where we are and what the future brings?
Kršek, A., Krpina, K., Miroslav, S., Detel, D., Batičić, L., & Tokmadžić, V. S. (2023) · Trends in Immunotherapy · doi:10.24294/ti.v7.i2.2186 · Cited by 2
Nasr, L. F., Zoghbi, M., Lazcano, R., Nakazawa, M. S., Bishop, A. J., Farooqi, A. S., Mitra, D., Guadagnolo, B. A., Benjamin, R. S., PATEL, S. R., et al. (2024) · Cancers · doi:10.3390/cancers16091763 · Cited by 3
Self-citationInduced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors
Zhang, X., Ding, T., Yang, F., Xu, H., Zhang, J., Bai, Y., Shi, Y., Yang, J., Chen, C., & Zhang, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02018-y · Cited by 2
Gong, Z., Xu, X., Cao, Y., Feng, Y., Liu, J., Yang, J., Wang, W., Gong, H., Li, ., Chen, L., et al. (2025) · Translational Cancer Research · doi:10.21037/tcr-24-1746 · Cited by 2
Management of Cutaneous Melanoma, With a Special Focus on Desmoplastic Melanoma
Kendra, K. L., Contreras, C. M., Verschraegen, C. F., Wu, R. C. H., & Hasanov, M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472752 · Cited by 3
Adjuvant Systemic Therapy for High-Risk Melanoma Patients
Najjar, Y. G., Massa, R. C., Sondak, V. K., Eggermont, A. M. M., Gogas, H. J., & Kirkwood, J. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_33-1 · Cited by 2
Bollin, K. B., & Margolin, K. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_14 · Cited by 2
Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
Keung, E. Z.-Y., Amaria, R. N., Sondak, V. K., Ross, M. I., Kirkwood, J. M., & Wargo, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_70 · Cited by 2
Self-citationNeoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
Xue, C., Dong, H., Chen, Y., Lu, X., Zheng, S., & Cui, H. (2022) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2022.06.779 · Cited by 2
Melanoma: An immunotherapy journey from bench to bedside
Navani, V., Graves, M. C., Mandaliya, H. A., Hong, M., van der Westhuizen, A., Martin, J. H., & Bowden, N. A. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_2 · Cited by 2
Czarnecka, A. M., Ostaszewski, K., Błoński, P. J., Szumera‐Ciećkiewicz, A., Kozak, K., Placzke, J., Borkowska, A. M., Terlecka, A. M., Rogala, P., Świtaj, T., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108382 · Cited by 3
Immune Checkpoint Inhibitors and Perioperative Considerations
Robinson, A., & Wolfe, R. C. (2020) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2020.08.007 · Cited by 2
Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Lynch, K., Hu, Y., Farrow, N. E., Song, Y., Meneveau, M. O., Kwak, M., Lowe, M., Bartlett, E. K., Beasley, G. M., Karakousis, G. C., et al. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27100 · Cited by 2
The impact of the immunotherapy revolution on lymph nodal surgery
Eggermont, A. M. M. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.05.013 · Cited by 2
Balko, J. M., Sun, X., Hanna, A., Ocampo, A. A., Taylor, B. C., Marshall, J., Steele, J., Axelrod, M. L., Wescott, E. C., Opalenik, S. R., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6926989/v1 · Cited by 2
Massi, D., & Tawbi, H. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2025.12.016 · Cited by 2
Self-citationNeoadjuvant Checkpoint Blockade in Lynch Syndrome–Related Pancreatic Adenocarcinoma
Childers, B. G., Valasek, M. A., Patel, H., & Lowy, A. M. (2021) · Pancreas · doi:10.1097/mpa.0000000000001742 · Cited by 1
Gu, J., Jian, H., Wei, C. Y., Shiu, J., Ganesan, A. K., Zhao, W., & Hedde, P. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087008 · Cited by 1
Zhou, J., & Wuthrick, E. J. (2024) · Cancers · doi:10.3390/cancers16173027 · Cited by 1
Perioperative Implications of Biologics and Immunotherapy
Idowu, O., Lewis, A., & Doyle, C. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.008 · Cited by 1
The evolving role of surgery in multimodal cancer treatment: a comprehensive review
Eskandar, K. (2024) · Surgery and Oncology · doi:10.17650/2949-5857-2024-14-4-55-62 · Cited by 1
Hyngstrom, J. R. (2024) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.11.003 · Cited by 1
An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma
McCombe, A., & van Akkooi, A. C. J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2522944 · Cited by 1
Cutaneous Melanoma Management—An Update and Narrative Review for the General Surgeon
Binks, M. J., van Akkooi, A. C. J., Menzies, A. M., & Spillane, A. J. (2025) · ANZ Journal of Surgery · doi:10.1111/ans.70252 · Cited by 1
Perioperative treatment strategies for advanced melanoma and nonmelanoma skin cancers
Sun, K. H., Thakker, S., Greenzaid, J. D., Belzberg, M., Miller, D. M., & Patel, V. A. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.09.098 · Cited by 1
Neoadjuvant therapy in skin cancer: current evidence and future perspectives
Daniello, L., Kleemann, J., & Schilling, B. (2026) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15968 · Cited by 1
Lymph node preservation as an immunotherapeutic catalyst
Zuha, A., Zhang, Y., Sun, Q., Zhu, W., Chen, B., Song, Y., Jin, B., Liu, Z. H., Wu, Z., Li, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105195 · Cited by 1
Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024–2033
Blezer, G., Patterson, K. W., MIčoch, T., Alahakoon, J., Lai, Y., Khurana, V., & Aguiar‐Ibáñez, R. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2634755 · Cited by 1
Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations
Uche, I. K., & Lyons, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052327 · Cited by 1
New paradigms in the management of melanoma throughout various stage of the disease
van Akkooi, A. C. J., & Eggermont, A. M. M. (2026) · Academia oncology. · doi:10.20935/acadonco8184 · Cited by 1
Postow, M. A., Zang, P. D., Pal, S. K., Mauguen, A., Farwell, M. D., Gordon, M. S., Hays, D., Wong, J. Y. C., Chen, D. L., Ulaner, G. A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012208 · Cited by 2
Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors
Okada, M., Yamasaki, S., Sato, G. R., Shimizu, K., & Fujii, S. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00842-9 · Cited by 1
Hoff, C. O., Heeke, S., Mitani, Y., de Sousa, L. G., Siqueira, J. M., Li, K., Bonini, F., Bell, D., Marques-Piubelli, M. L., Lin, S., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4599 · Cited by 3
Self-citationUncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma
Țăpoi, D. A., Lambrescu, I. M., Manole, C. G., Gaina, G. F., & Ceafalan, L. C. (2026) · Medicina · doi:10.3390/medicina62040739 · Cited by 2
Hu, Y., Liu, L., Li, Z., Liu, J., Yang, C., & Shao, L. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115767 · Cited by 1
Ibraheim, H., d’Arienzo, P. D., Dean, N. J., Duggleby, W., Singh, A., Manickavasagar, T., Kalofonou, F., Aboulela, M., Vadera, S., Anderson, K. E., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116795 · Cited by 1
Advances in Cancer Immunotherapy for Solid Tumors
Gabizon–Peretz, S., & Kluger, H. M. (2026) · Advanced Science · doi:10.1002/advs.76020 · Cited by 1
Potter, L. M., Lopez-Olivo, M. A., uppal, R. S., Beeler, D., Thong, M. S. Y., Phan, B., Chou, Y.-J., Krause, K. J., Tanveer, A., Hussain, H. U., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10996-1 · Cited by 1
Coyle, A. H., Hutton, D. W., Buchakjian, M. R., Casper, K. A., Forner, D. W. A., Hawley, S. T., Neal, M. E. H., Malloy, K. M., Mierzwa, M. L., Prince, M. E., et al. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.2124 · Cited by 1
Impact of Acute and Chronic Adverse Events on Quality of Life in Cutaneous Melanoma
Zamfirescu-Deryder, A.-M., Bîlteanu, L., Moga, V.-L., Folea, A.-R., Zamfirescu, A., Toma, R.-V., Marinescu, Ș., Barascu, S., Șerban, A. I., & Anghel, R. (2026) · Cancers · doi:10.3390/cancers18162619 · Cited by 1
Quoi de neuf en oncodermatologie?
Robert, C. (2018) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)31288-2 · Cited by 1
Gao, Y., Xiao, H., Meng, W., Liao, J., Chen, Q., Zhao, G., Li, C., & Bai, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1131690 · Cited by 1
Selecting Triple Negative Breast Cancer Patients for Immunotherapy
Downs‐Canner, S., & Mittendorf, E. A. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.05.005 · Cited by 1
Translational and clinical applications of the GeoMx digital spatial profiling platform
Church, S., Perez, J., Murphy, B., Sato, H., Warren, S. E., & Beechem, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00034-1 · Cited by 1
Cui, S., Sun, X., & Gao, J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2336106 · Cited by 1
Tang, Y.-H., Bergmann, J. P., Vaidya, D. M., & Faraday, N. R. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001068 · Cited by 1
Transarterial Chemoembolization in Locally Advanced Rectal Cancer: A Systematic Review
Temperley, H. C., Bell, J., Cuddihy, T. O., O’Sullivan, N. J., Curtain, B. M. M., Dolan, S. G., McEniff, N. J., Brennan, I. M., Sheahan, K. P., Marshall, M., et al. (2024) · Onco · doi:10.3390/onco4040029 · Cited by 1
Asl, A. S., Davari, M., Ghorbani, A., Seddighi, N., Arabi, K., & Saburi, E. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113790 · Cited by 1
Advances in Lipid-Based Nanosystems for Immune Induction in Cancer Immunotherapy
Bhatt, P., Kaurav, M., & Singh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_14 · Cited by 1
Lésions pseudotumorales induites par des agents pathogènes. Introduction
Hofman, P. M., & Tauziède‐Espariat, A. (2019) · Annales de Pathologie · doi:10.1016/j.annpat.2019.03.004 · Cited by 1
Nonsurgical Management of Lymph Node Basins in Melanoma
Habashi, R., & Francescutti, V. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.008 · Cited by 1
Adjuvant and neoadjuvant treatment of melanoma
Koelblinger, P. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00602-3 · Cited by 1
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
